Bristol-Myers Squibb Company (BMY)

Now could be a great time to scoop up three stocks trading way below their previous peaks.

These two stocks have had their issues in recent years, but both look like reliable long-term bets.

Bristol Myers Squibb Company BMY is experiencing a good run of late after touching a 52-week low of $39.35 on July 5. This short rally has given anxious investors a ray of hope. The biotech giant has been...

Bristol-Myers Squibb has underperformed the S&P 500 over the past year, and analysts are cautious about the stock’s prospects.

Zenas is a Bristol Meyers Squibb-backed pharma company that is about to go public. Its treatment provides solid differentiation that could rival competitors.

These dividend payers could more than double their payouts in the decade ahead.

Investors in Bristol-Myers Squibb Company BMY need to pay close attention to the stock based on moves in the options market lately. That is because the Sep 20, 2024 $70 Put had some of the highest implied...

A strong pipeline of products could potentially transform these companies, but there are risks.

AbbVie has recently outperformed the Nasdaq, and Wall Street analysts are moderately optimistic about the stock’s prospects.

Rebounding growth could make shares of this leading drugmaker a big winner.